bioAffinity Technologies (BIAF) Projected to Release Quarterly Earnings on Wednesday

bioAffinity Technologies (NASDAQ:BIAF) will likely be posting its Q2 2026 results before the market opens on Wednesday, August 19th. Analysts expect bioAffinity Technologies to announce earnings of ($2.10) per share and revenue of $1.7010 million for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Friday, August 7, 2026 at 8:30 AM ET.

bioAffinity Technologies (NASDAQ:BIAF) last announced its quarterly earnings data on Friday, August 7th. The company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($2.10) by $1.46. The business had revenue of $1.51 million for the quarter, compared to analyst estimates of $1.70 million. bioAffinity Technologies had a negative net margin of 257.30% and a negative return on equity of 196.80%.

bioAffinity Technologies Stock Down 0.8%

BIAF opened at $0.49 on Wednesday. bioAffinity Technologies has a twelve month low of $0.46 and a twelve month high of $13.50. The company’s 50-day moving average price is $0.88 and its two-hundred day moving average price is $1.63. The stock has a market cap of $2.30 million, a price-to-earnings ratio of -0.07 and a beta of -1.05. The company has a quick ratio of 1.34, a current ratio of 1.36 and a debt-to-equity ratio of 0.15.

Hedge Funds Weigh In On bioAffinity Technologies

A hedge fund recently bought a new position in bioAffinity Technologies stock. Scientech Research LLC bought a new position in bioAffinity Technologies, Inc. (NASDAQ:BIAF) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 16,583 shares of the company’s stock, valued at approximately $49,000. Scientech Research LLC owned approximately 0.46% of bioAffinity Technologies as of its most recent SEC filing. 1.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the stock. Wall Street Zen raised shares of bioAffinity Technologies from a “sell” rating to a “hold” rating in a report on Monday. Weiss Ratings reissued a “sell (e+)” rating on shares of bioAffinity Technologies in a research report on Monday, July 20th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.